Introduction. Primary bone tumours of the distal radius are rare, while it remains the third commonest site for primary lesions and recurrences of Giant Cell Tumours (GCT). The functional demands on the hand make reconstruction of the wrist joint following the excision of distal radius, particularly challenging. Methods. A single-centre retrospective study, reporting the functional and oncological outcomes of six patients (4 males, 2 females - mean age of 53 (22 to 79)) who underwent a custom-made endoprosthetic replacement of the distal radius with arthrodesis at our institution, during 1999 - 2010. Five patients were diagnosed with primary bone sarcoma of the distal radius (4 GCTs, 1 osteosarcoma) and another had a metastatic lesion from a primary renal cell carcinoma. The diagnosis was confirmed by needle biopsy in all cases. We assessed the patients' functional outcomes using the Musculoskeletal Tumour Society scoring system (MSTS) and the Toronto Extremity Salvage Score (TESS). Results. The mean follow-up was 3 years (up to 9.5 years). One patient died of unrelated medical causes, age 89, and one patient succumbed to renal carcinoma, age 53 (9.5 and 4 years post-operatively). All prostheses remained clinically and radiologically stable. One-year radiographs confirmed bone remodelling and osseointegration at the bone-prosthesis interface. There were no cases of local recurrence, metastases, infection or wound complications post-operatively. The mean functional outcome scores were: MSTS 73% (71 to 78), TESS 75% (73 to 79). Pain-free hand movements were restored in all cases. Discussion. Reconstruction options include curettage with/without grafting or cementing, ulna translocation, autografts (vascularised or non-vascularised ⊞/⊟ arthrodesis), allografts, custom-made megaprostheses. Custom-made endoprosthetic reconstruction of the distal radius with wrist arthrodesis following bone tumour resection represents a viable and versatile treatment option. Satisfactory outcomes are achieved with acceptable risks and functional outcomes; especially when considering the nature of the diagnosis and alternative treatment options

Aims

Local recurrence remains a challenging and common problem following curettage and joint-sparing surgery for giant cell tumour of bone (GCTB). We previously reported a 15% local recurrence rate at a median follow-up of 30 months in 20 patients with high-risk GCTB treated with neoadjuvant Denosumab. The aim of this study was to determine if this initial favourable outcome following the use of Denosumab was maintained with longer follow-up.